http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2001504-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5dd388a5130b0bdede0fdfc6c2af6ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7452 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 |
| filingDate | 2007-03-15^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7449dca35bc305786e53d98bc5973f1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7933d1fe40a037c43d706faf9282ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30fdca406466bb6b6f81349124522a4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f9cff36af9353e8660b635896315d1e |
| publicationDate | 2008-12-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2001504-A2 |
| titleOfInvention | Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
| abstract | The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. |
| priorityDate | 2006-03-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 197 of 197.